TY - JOUR
T1 - Somatic Fas mutations in non-Hodgkin's lymphoma
T2 - association with extranodal disease and autoimmunity
AU - Grønbaek, K
AU - Straten, P T
AU - Ralfkiaer, E
AU - Ahrenkiel, V
AU - Andersen, M K
AU - Hansen, N E
AU - Zeuthen, J
AU - Hou-Jensen, K
AU - Guldberg, P
N1 - Copyright 1998 by The American Society of Hematology
PY - 1998/11/1
Y1 - 1998/11/1
N2 - Fas (APO-1/CD95) is a cell-surface receptor involved in cell death signaling. Germline mutations in the Fas gene have been associated with autoimmune lymphoproliferative syndrome, and somatic Fas mutations have been found in multiple myeloma. We have examined the entire coding region and all splice sites of the Fas gene in 150 cases of non-Hodgkin's lymphoma. Overall, mutations were identified in 16 of the tumors (11%). Missense mutations within the death domain of the receptor were associated with retention of the wild-type allele, indicating a dominant-negative mechanism, whereas missense mutations outside the death domain were associated with allelic loss. Fas mutations were identified in 3 (60%) MALT-type lymphomas, 9 (21%) diffuse large B-cell lymphomas, 2 (6%) follicle center cell lymphomas, 1 (50%) anaplastic large cell lymphoma, and 1 unusual case of B-cell chronic lymphocytic leukemia with a marked tropism for skin. Among the 16 patients with somatic Fas mutations, 15 showed extranodal disease at presentation, and 6 relapsed in extranodal areas. Ten of 13 evaluable patients showed features suggestive of autoreactive disease. Our data indicate that somatic disruption of Fas may play a role in the pathogenesis of some lymphomas, and suggest a link between Fas mutation, cancer and autoimmunity.
AB - Fas (APO-1/CD95) is a cell-surface receptor involved in cell death signaling. Germline mutations in the Fas gene have been associated with autoimmune lymphoproliferative syndrome, and somatic Fas mutations have been found in multiple myeloma. We have examined the entire coding region and all splice sites of the Fas gene in 150 cases of non-Hodgkin's lymphoma. Overall, mutations were identified in 16 of the tumors (11%). Missense mutations within the death domain of the receptor were associated with retention of the wild-type allele, indicating a dominant-negative mechanism, whereas missense mutations outside the death domain were associated with allelic loss. Fas mutations were identified in 3 (60%) MALT-type lymphomas, 9 (21%) diffuse large B-cell lymphomas, 2 (6%) follicle center cell lymphomas, 1 (50%) anaplastic large cell lymphoma, and 1 unusual case of B-cell chronic lymphocytic leukemia with a marked tropism for skin. Among the 16 patients with somatic Fas mutations, 15 showed extranodal disease at presentation, and 6 relapsed in extranodal areas. Ten of 13 evaluable patients showed features suggestive of autoreactive disease. Our data indicate that somatic disruption of Fas may play a role in the pathogenesis of some lymphomas, and suggest a link between Fas mutation, cancer and autoimmunity.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Alleles
KW - Amino Acid Substitution
KW - Apoptosis
KW - Autoimmune Diseases/complications
KW - Autoimmunity/genetics
KW - Codon/genetics
KW - DNA Mutational Analysis
KW - DNA, Neoplasm/genetics
KW - Female
KW - Genetic Predisposition to Disease
KW - Humans
KW - Lymphoma, Non-Hodgkin/classification
KW - Male
KW - Middle Aged
KW - Mutation, Missense
KW - Neoplasm Proteins/genetics
KW - Paraneoplastic Syndromes/etiology
KW - Polymorphism, Genetic
KW - Protein Structure, Tertiary
KW - RNA Splicing/genetics
KW - Reverse Transcriptase Polymerase Chain Reaction
KW - Sjogren's Syndrome/complications
KW - Thyroiditis, Autoimmune/complications
KW - fas Receptor/genetics
M3 - Journal article
C2 - 9787134
SN - 0006-4971
VL - 92
SP - 3018
EP - 3024
JO - Blood
JF - Blood
IS - 9
ER -